July 4, 2024

CSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe

MARBURG, Germany, July 04, 2024 (GLOBE NEWSWIRE) — Global biotechnology leader CSL Behring (ASX: CSL) today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the first gene therapy administered as a treatment in a real-world setting for hemophilia B in Europe. […]

Read More »

Government invests GHC 6 billion in TVET

The government has Since 2017 invested more than GHC6 billion in the technical and vocational education and training sectors.

The investment has resulted in improvements to infrastructure at TVET schools, the provision of state-of-the-art laboratorie…

Read More »

Recent Posts